The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2017 | Durvalumab: the new standard of care for NSCLC?
Johan Vansteenkiste, MD, PhD, from the University Hospitals Leuven, Leuven, Belgium, discussesthe PACIFIC trial (NCT02125461) at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. Non-small cell lung cancer (NSCLC) patients are typically treated with a combination of chemotherapy and radiotherapy, however a significant number of these patients relapse. The PACIFC study investigated the efficacy of durvalumab compared with a placebo as consolidation therapy after chemotherapy for stage 3 NSCLC. The results showed a significant improvement in progression free survival, as well as an impressive hazard ratio.
